Biological rationale for the design of polymeric anti-cancer nanomedicines

Journal of Drug Targeting

Volumn 21, Issue 1, 2013, Pages 1-26

  Zhou, Yan ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Cancer heterogeneity; Cancer stem cells; EPR effect; Metastasis; Nanomedicines; Polymer conjugates; Targeting; Tumor microenvironment

Indexed keywords

ALENDRONIC ACID; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLOPAMINE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; GADOLINIUM; GAMMA SECRETASE INHIBITOR; GEMCITABINE; GONADORELIN; IMATINIB; IRINOTECAN; LIPOSOME; MACROGOL; NANOCARRIER; PACLITAXEL; PLATINUM; SALINOMYCIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB;

ANGIOGENESIS; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL INTERACTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; GROWTH INHIBITION; HUMAN; METASTASIS; NANOMEDICINE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; NEOPLASTIC STEM CELLS; PERMEABILITY; POLYMERS;

EID: 84872036618     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.723213     Document Type: Review

References (227)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identifcation of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100, 3983-3988.
2. Alitalo K, Tammela T, Petrova T V. (2005). Lymphangiogenesis in development and human disease. Nature, 438, 946-953.
3. Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2, 750-763.
4. Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380.
5. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM. (2010). Termal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med, 2, 55ra79.
6. Bacac M, Stamenkovic I. (2008). Metastatic cancer cell. Annu Rev Pathol, 3, 221-247.
7. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P, Rosato A. (2008). A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer afords a potent in vivo therapeutic activity. Clin Cancer Res, 14, 3598-3606.
8. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
9. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 25, 2524-2533.
10. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. (2007). Impact of tumor-specifc targeting on the biodistribution and efcacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA, 104, 15549-15554.
11. Blanco E, Hsiao A, Ruiz-Esparza GU, Landry MG, Meric-Bernstam F, Ferrari M. (2011). Molecular-targeted nanotherapies in cancer: enabling treatment specifcity. Mol Oncol, 5, 492-503.
12. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 3, 730-737.
13. Bourseau-Guilmain E, Béjaud J, Griveau A, Lautram N, Hindré F, Weyland M, Benoit JP, Garcion E. (2012). Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm, 423, 93-101.
14. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. (2005). Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer, 5, 744-749.
15. Broxterman HJ, Gotink KJ, Verheul HM. (2009). Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat, 12, 114-126.
16. Bruce WR, Van Der Gaag H. (1963). A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature, 199, 79-80.
17. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL. (2002). Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res, 62, 6831-6836.
18. Canal F, Sanchis J, Vicent MJ. (2011). Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol, 22, 894-900.
19. Chambers AF, Groom AC, MacDonald IC. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2, 563-572.
20. Chandna P, Khandare JJ, Ber E, Rodriguez-Rodriguez L, Minko T. (2010). Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res, 27, 2296-2306.
21. Cho K, Wang X, Nie S, Chen ZG, Shin DM. (2008). Terapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res, 14, 1310-1316.
22. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY. (2010). Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials, 31, 106-114.
23. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, Vanpelt H, Flessner MF. (2006). Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res, 12, 1906-1912.
24. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang V P, Soong T, Lin YM, Horng C F. (2006). Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res, 12, 2706-2715.
25. Chytil P, Etrych T, Kríž J, Šubr V, Ulbrich K. (2010). N-(2-Hydroxypropyl) methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specifc or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur J Pharm Sci, 41, 473-482.
26. Clevers H. (2011). The cancer stem cell: premises, promises and challenges. Nat Med, 17, 313-319.
27. Collins AT, Maitland NJ. (2009). Prostate cancer: regeneration of interest in the prostate. Nat Rev Urol, 6, 184-186.
28. Collins I, Workman P. (2006). New approaches to molecular cancer therapeutics. Nat Chem Biol, 2, 689-700.
29. Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S, Verderio P. (2010). HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacol Res, 62, 150-165.
30. David A, Kopecková P, Rubinstein A, Kopecek J. (2001). Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem, 12, 890-899.
31. Davies C de L, Lundstrøm LM, Frengen J, Eikenes L, Burland ØS, Kaalhus O, Hjelstuen MH, Brekken C. (2004). Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res, 64, 547-553.
32. Davis ME. (2009). The frst targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm, 6, 659-668.
33. Dean M, Fojo T, Bates S. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer, 5, 275-284.
34. Dick JE. (2008). Stem cell concepts renew cancer research. Blood, 112, 4793-4807.
35. Dick JE. (2009). Looking ahead in cancer stem cell research. Nat Biotechnol, 27, 44-46.
36. Duncan R, Gaspar R. (2011). Nanomedicine(s) under the microscope. Mol Pharm, 8, 2101-2141.
37. Dvorák M, Kopecková P, Kopecek J. (1999). High-molecular weight HPMA copolymer-adriamycin conjugates. J Control Release, 60, 321-332.
38. Edlund M, Sung SY, Chung LW. (2004). Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem, 91, 686-705.
39. Ehrlich P. (1906). Studies in Immunity. New York: Plenum Press.
40. ElBayoumi TA, Torchilin VP. (2009). Tumor-targeted nanomedicines: enhanced antitumor efcacy in vivo of doxorubicin-loaded, long-circulating liposomes modifed with cancer-specifc monoclonal antibody. Clin Cancer Res, 15, 1973-1980.
41. Etrych T, Chytil P, Mrkvan T, Šírová M, Ríhová B, Ulbrich K. (2008). Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. J Control Release, 132, 184-192.
42. Etrych T, Šubr V, Strohalm J, Šírová M, Ríhová B, Ulbrich K. (2012). HPMA copolymer-doxorubicin conjugates: The efects of molecular weight and architecture on biodistribution and in vivo activity. J Control Release, DOI: 10.1016/j.jconrel.2012.06.029.
43. Fang J, Nakamura H, Maeda H. (2011). The EPR efect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the efect. Adv Drug Deliv Rev, 63, 136-151.
44. Fang J, Sawa T, Maeda H. (2003). Factors and mechanism of "EPR" efect and the enhanced antitumor efects of macromolecular drugs including SMANCS. Adv Exp Med Biol, 519, 29-49.
45. Feld R, Rubinstein LV, Weisenberger TH. (1984). Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol, 2, 1352-1358.
46. Folkman J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31.
47. Friedl P, Alexander S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 147, 992-1009.
48. Furth J, Kahn M. (1937). The transmission of leukemia of mice with a single cell. Am J Cancer, 31, 276-282.
49. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. (2003). In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res, 9, 6551-6559.
50. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, Radtke F, Aifantis I. (2009). Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell, 4, 548-558.
51. Gao J, Sun J, Li H, Liu W, Zhang Y, Li B, Qian W, Wang H, Chen J, Guo Y. (2010). Lyophilized HER2-specifc PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials, 31, 2655-2664.
52. Gao SQ, Lu ZR, Petri B, Kopecková P, Kopecek J. (2006). Colon-specifc 9-aminocamptothecin-HPMA copolymer conjugates containing a 1, 6-elimination spacer. J Control Release, 110, 323-331.
53. Gao SQ, Lu ZR, Kopecková P, Kopecek J. (2007). Biodistribution and pharmacokinetics of colon-specifc HPMA copolymer-9-aminocamptothecin conjugate in mice. J Control Release, 117, 179-185.
54. Gao SQ, Sun Y, Kopecková P, Peterson CM, Kopecek J. (2008). Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specifc HPMA copolymer-9-AC conjugate in rats. Pharm Res, 25, 218-226.
55. Gao SQ, Sun Y, Kopecková P, Peterson CM, Kopecek J. (2009). Antitumor efcacy of colon-specifc HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromol Biosci, 9, 1135-1142.
56. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. (1996). Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol, 14, 2353-2364.
57. Goda K, Fenyvesi F, Bacsó Z, Nagy H, Márián T, Megyeri A, Krasznai Z, Juhász I, Vecsernyés M, Szabó G Jr. (2007). Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ter, 320, 81-88.
58. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 19, 3312-3322.
59. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23, 7794-7803.
60. Greco F, Vicent MJ, Gee S, Jones AT, Gee J, Nicholson RI, Duncan R. (2007). Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release, 117, 28-39.
61. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. (2009). Identifcation of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645-659.
62. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 146, 633-644.
63. Hanahan D, Coussens LM. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21, 309-322.
64. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell, 100, 57-70.
65. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674.
66. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med, 348, 2491-2499.
67. Hashizume H, Baluk P, Morikawa S, McLean JW, Turston G, Roberge S, Jain RK, McDonald DM. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 156, 1363-1380.
68. Heidel JD, Davis ME. (2011). Clinical developments in nanotechnology for cancer therapy. Pharm Res, 28, 187-199.
69. Heldin CH, Rubin K, Pietras K, Ostman A. (2004). High interstitial fuid pressure-an obstacle in cancer therapy. Nat Rev Cancer, 4, 806-813.
70. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. (2006). Metastatic patterns in adenocarcinoma. Cancer, 106, 1624-1633.
71. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. (2004). A distinct "side population" of cells with high drug efux capacity in human tumor cells. Proc Natl Acad Sci USA, 101, 14228-14233.
72. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG. (2009). Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell, 4, 559-567.
73. Hongrapipat J, Kopecková P, Liu J, Prakongpan S, Kopecek J. (2008a). Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm, 5, 696-709.
74. Hongrapipat J, Kopecková P, Prakongpan S, Kopecek J. (2008b). Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. Int J Pharm, 351, 259-270.
75. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podolof D, Goris M. (2005). Efcacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol, 23, 712-719.
76. Hsu MJ, Juliano RL. (1982). Interactions of liposomes with the reticuloendothelial system. II: Nonspecifc and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta, 720, 411-419.
77. Hütter ML, Schlenk RF. (2011). Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. Expert Opin Biol Ter, 11, 1369-1380.
78. Iliopoulos D, Hirsch HA, Wang G, Struhl K. (2011). Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA, 108, 1397-1402.
79. Jain RK. (1987). Transport of molecules across tumor vasculature. Cancer Metastasis Rev, 6, 559-593.
80. Jain RK. (1988). Determinants of tumor blood fow: a review. Cancer Res, 48, 2641-2658.
81. Jain RK. (1998). Delivery of molecular and cellular medicine to solid tumors. J Control Release, 53, 49-67.
82. Jain RK, Munn LL, Fukumura D. (2002). Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer, 2, 266-276.
83. Jain RK, Tong RT, Munn LL. (2007). Efect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res, 67, 2729-2735.
84. Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol, 7, 653-664.
85. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
86. Johnson RN, Kopecková P, Kopecek J. (2009). Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug Chem, 20, 129-137.
87. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. (1992). Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res, 52, 5144-5153.
88. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3, 537-549.
89. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. (2007). Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA, 104, 3460-3465.
90. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. (2004). Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature, 431, 707-712.
91. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, 6732-6740.
92. Klein CA. (2009). Parallel progression of primary tumours and metastases. Nat Rev Cancer, 9, 302-312.
93. Kopecek J, Kopecková P. (2010). HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev, 62, 122-149.
94. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. (2008). GATA-3 links tumor diferentiation and dissemination in a luminal breast cancer model. Cancer Cell, 13, 141-152.
95. Kwon IK, Lee SC, Han B, Park K. (2012). Analysis on the current status of targeted drug delivery to tumors. J Control Release, DOI: 10.1016/j. jconrel.2012.07.010.
96. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, Hofman RM, Ruoslahti E. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA, 101, 9381-9386.
97. Lammers T. (2010). Improving the efcacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev, 62, 203-230.
98. Lammers T, Peschke P, Kühnlein R, Šubr V, Ulbrich K, Debus J, Huber P, Hennink W, Storm G. (2007). Efect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J Control Release, 117, 333-341.
99. Lammers T, Hennink WE, Storm G. (2008). Tumour-targeted nanomedicines: principles and practice. Br J Cancer, 99, 392-397.
100. Lammers T, Šubr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G. (2009). Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials, 30, 3466-3475.
101. Lammers T, Kiessling F, Hennink WE, Storm G. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release, 161, 175-187.
102. Lee YJ, Galoforo SS, Berns CM, Erdos G, Gupta AK, Ways DK, Corry PM. (1995). Efect of ionizing radiation on AP-1 binding activity and basic fbroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells. J Biol Chem, 270, 28790-28796.
103. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res, 60, 4324-4327.
104. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309.
105. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, Jain RK. (1992). Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fuid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res, 52, 6553-6560.
106. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S. (2000). Tumor irradiation enhances the tumor-specifc distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efcacy. Clin Cancer Res, 6, 2829-2834.
107. Li SD, Huang L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm, 5, 496-504.
108. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. (2011). A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ter, 11, 464-473.
109. Liu J, Kopecková P, Bühler P, Wolf P, Pan H, Bauer H, Elsässer-Beile U, Kopecek J. (2009). Biorecognition and subcellular trafcking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm, 6, 959-970.
110. Lu ZR, Kopecková P, Kopecek J. (1999). Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat Biotechnol, 17, 1101-1104.
111. Luo K, Yang J, Kopecková P, Kopecek J. (2011). Biodegradable Multiblock Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition-Fragmentation Chain Transfer Polymerization and Click Chemistry. Macromolecules, 44, 2481-2488.
112. Maduro JH, Pras E, Willemse PH, de Vries EG. (2003). Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev, 29, 471-488.
113. Maeda H, Matsumura Y, Kato H. (1988). Purifcation and identifcation of [hydroxyprolyl3]bradykinin in ascitic fuid from a patient with gastric cancer. J Biol Chem, 263, 16051-16054.
114. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR efect in macromolecular therapeutics: a review. J Control Release, 65, 271-284.
115. Malugin A, Kopecková P, Kopecek J. (2006). HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function. Mol Pharm, 3, 351-361.
116. Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, Fortelius LE, Landor S, Toivola DM, Lindén M, Sahlgren C. (2011). Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ter, 19, 1538-1546.
117. Matsumura Y, Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46, 6387-6392.
118. Matsumura Y, Kataoka K. (2009). Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci, 100, 572-579.
119. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefeld XO, Jain RK. (2006). Degradation of fbrillar collagen in a human melanoma xenograft improves the efcacy of an oncolytic herpes simplex virus vector. Cancer Res, 66, 2509-2513.
120. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. (2004). Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage diferentiation. Toxicol Sci, 82, 341-358.
121. Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R. (2011). Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm, 8, 1052-1062.
122. Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer, 6, 583-592.
123. Minko T, Kopecková P, Kopecek J. (1999). Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release, 59, 133-148.
124. Minko T, Kopecková P, Kopecek J. (2000). Efcacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer, 86, 108-117.
125. Minko T, Kopecková P, Kopecek J. (2001). Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release, 71, 227-237.
126. Mundy GR. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2, 584-593.
127. Nadali F, Pourfathollah AA, Alimoghaddam K, Nikougoftar M, Rostami S, Dizaji A, Azizi E, Zomorodipour A, Ghavamzadeh A. (2007). Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology, 12, 393-401.
128. Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R. (2011). Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Tromb Vasc Biol, 31, 750-757.
129. Neri D, Bicknell R. (2005). Tumour vascular targeting. Nat Rev Cancer, 5, 436-446.
130. Nguyen DX, Bos PD, Massagué J. (2009). Metastasis: from dissemination to organ-specifc colonization. Nat Rev Cancer, 9, 274-284.
131. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, Tsien RY. (2010). Surgery with molecular fuorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA, 107, 4317-4322.
132. Nishiyama N, Nori A, Malugin A, Kasuya Y, Kopecková P, Kopecek J. (2003). Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce diferent stress responses in A2780 human ovarian carcinoma cells. Cancer Res, 63, 7876-7882.
133. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. (1998). Early phase tumor accumulation of macromolecules: a great diference in clearance rate between tumor and normal tissues. Jpn J Cancer Res, 89, 307-314.
134. Northfelt DW, Dezube BJ, Tommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol, 16, 2445-2451.
135. Nowell PC. (1976). The clonal evolution of tumor cell populations. Science, 194, 23-28.
136. Nowotnik DP, Cvitkovic E. (2009). ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Terapeutic. Adv Drug Deliv Rev, 61, 1214-1219.
137. Nugent LJ, Jain RK. (1984). Extravascular difusion in normal and neoplastic tissues. Cancer Res, 44, 238-244.
138. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodefcient mice. Nature, 445, 106-110.
139. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. (2004). Reduced cardiotoxicity and comparable efcacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for frst-line treatment of metastatic breast cancer. Ann Oncol, 15, 440-449.
140. O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW. (2008). Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Torac Oncol, 3, 728-734.
141. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Grifths J, Tuveson DA. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324, 1457-1461.
142. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY. (2010). Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fuorescence and MR imaging of proteases. Proc Natl Acad Sci USA, 107, 4311-4316.
143. Omelyanenko V, Kopecková P, Gentry C, Kopecek J. (1998a). Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release, 53, 25-37.
144. Omelyanenko V, Gentry C, Kopecková P, Kopecek J. (1998b). HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer, 75, 600-608.
145. Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames HM, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ, Ross TS. (2009). Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell, 16, 137-148.
146. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 296, 1883-1886.
147. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. (2004). Pathology: cancer cells compress intratumour vessels. Nature, 427, 695.
148. Pan H, Sima M, Kopecková P, Wu K, Gao S, Liu J, Wang D, Miller SC, Kopecek J. (2008). Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm, 5, 548-558.
149. Pan H, Yang J, Kopecková P, Kopecek J. (2011). Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules, 12, 247-252.
150. Pegram MD, Konecny G, Slamon DJ. (2000). The molecular and cellular biology of HER2/neu gene amplifcation/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res, 103, 57-75.
151. Peschke P, Klein V, Wolber G, Friedrich E, Hahn EW. (1999). Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia. Histol Histopathol, 14, 461-469.
152. Pierce GB, Wallace C. (1971). Diferentiation of malignant to benign cells. Cancer Res, 31, 127-134.
153. Pluen A, Netti PA, Jain RK, Berk DA. (1999). Difusion of macromolecules in agarose gels: comparison of linear and globular confgurations. Biophys J, 77, 542-552.
154. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. (2005). The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res, 11, 8782-8788.
155. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hof DD, Hingorani SR. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 21, 418-429.
156. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ. (1981). Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res, 41, 487-494.
157. Rejmanová P, Pohl J, Baudyš M, Kostka V, Kopecek J. (1983). Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem, 184, 2009-2020.
158. Ren Y, Wang Y, Zhang Y, Wei D. (2008). Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro and in vivo. Mol Pharm, 5, 579-587.
159. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111.
160. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Bifoni M, Todaro M, Peschle C, De Maria R. (2007). Identifcation and expansion of human colon-cancer-initiating cells. Nature, 445, 111-115.
161. Ricci-Vitiani L, Pallini R, Bifoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. (2010). Tumour vascularization via endothelial diferentiation of glioblastoma stem-like cells. Nature, 468, 824-828.
162. Ríhová B, Kopecková P, Strohalm J, Rossmann P, Vetvicka V, Kopecek J. (1988). Antibody-directed afnity therapy applied to the immune system: in vivo efectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin Immunol Immunopathol, 46, 100-114.
163. Ríhová B, Strohalm J, Hoste K, Jelínková M, Hovorka O, Kovár M, Plocová D, Šírová M, Št'astný M, Schacht E, Ulbrich K. (2001). Immunoprotective therapy with targeted anticancer drugs. Macromolecular Symposia, 172, 21-28.
164. Roberts WG, Palade GE. (1997). Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res, 57, 765-772.
165. Rosen JM, Jordan CT. (2009). The increasing complexity of the cancer stem cell paradigm. Science, 324, 1670-1673.
166. + hematologic malignancies: the German Hodgkin Study Group experience. Blood, 120, 1470-1472.
167. Ruoslahti E. (2012). Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater, 24, 3747-3756.
168. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischof J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. (2003). From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA, 100, 7737-7742.
169. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. (2012). Treating metastatic cancer with nanotechnology. Nat Rev Cancer, 12, 39-50.
170. Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, Kopecek J, Satchi-Fainaro R. (2009). Targeting angiogenesis-dependent calcifed neoplasms using combined polymer therapeutics. PLoS ONE, 4, e5233.
171. Seymour LW, Duncan R, Strohalm J, Kopecek J. (1987). Efect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res, 21, 1341-1358.
172. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R. (1995). Infuence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer, 31A, 766-770.
173. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ; Cancer Research Campaign Phase I/II Clinical Trials committee. (2002). Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol, 20, 1668-1676.
174. Shackleton M, Quintana E, Fearon ER, Morrison SJ. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 138, 822-829.
175. Shah N P, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest, 117, 2562-2569.
176. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141, 69-80.
177. Sharkey RM, Goldenberg DM. (2006). Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin, 56, 226-243.
178. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release, 61, 145-157.
179. 6 and adriamycin conjugates in combination treatments. Clin Cancer Res, 6, 1008-1015.
180. Shiah JG, Dvorák M, Kopecková P, Sun Y, Peterson CM, Kopecek J. (2001a). Biodistribution and antitumour efcacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer, 37, 131-139.
181. Shiah JG, Sun Y, Kopecková P, Peterson CM, Straight RC, Kopecek J. (2001b). Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. J Control Release, 74, 249-253.
182. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. (2004). Identifcation of human brain tumour initiating cells. Nature, 432, 396-401.
183. Sorbera LA, Graul A, Silvestre J, Castañer J. (1999). Oncolytic, antiarthritic, matrix metalloproteinase inhibitor. Drugs Fut, 24, 16.
184. Spano D, Zollo M. (2012). Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis, 29, 381-395.
185. St Croix B, Man S, Kerbel RS. (1998). Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett, 131, 35-44.
186. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey R F, Ruoslahti E. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 16, 510-520.
187. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. (2010). Coadministration of a tumor-penetrating peptide enhances the efcacy of cancer drugs. Science, 328, 1031-1035.
188. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-234.
189. Tammela T, Alitalo K. (2010). Lymphangiogenesis: Molecular mechanisms and future promise. Cell, 140, 460-476.
190. Tang C, Ang BT, Pervaiz S. (2007). Cancer stem cell: target for anti-cancer therapy. FASEB J, 21, 3777-3785.
191. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. (2007). Coencapsulation of irinotecan and foxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta, 1768, 678-687.
192. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L. (2009). In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efcacy. Leuk Res, 33, 129-139.
193. Tassa C, Shaw SY, Weissleder R. (2011). Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res, 44, 842-852.
194. Taurin S, Nehof H, Greish K. (2012). Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release, DOI: 10.1016/j.jconrel.2012.07.013.
195. Teng Y, Wang X, Wang Y, Ma D. (2010). Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun, 392, 373-379.
196. Tayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425, 851-856.
197. Tompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI. (2010). Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ter, 9, 3052-3064.
198. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res, 41, 1967-1972.
199. Ulbrich K, Etrych T, Chytil P, Jelínková M, Ríhová B. (2003). HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release, 87, 33-47.
200. Ulbrich K, Šubr V. (2010). Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev, 62, 150-166.
201. Veiseh O, Kievit FM, Ellenbogen RG, Zhang M. (2011). Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev, 63, 582-596.
202. Vergote IB, Micha J P, Pippitt Jr CH, Rao GG, Spitz DL, Reed N, Dark GG, Garcia A, Maslyar DJ, Rustin GJ. (2010). Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. J Clin Oncol, 28(15suppl), abstract5013.
203. Vicent MJ, Greco F, Nicholson RI, Paul A, Grifths PC, Duncan R. (2005). Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl, 44, 4061-4066.
204. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res, 68, 9078-9086.
205. Vinogradov S, Wei X. (2012). Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond), 7, 597-615.
206. Wagner V, Dullaart A, Bock AK, Zweck A. (2006). The emerging nanomedicine landscape. Nat Biotechnol, 24, 1211-1217.
207. Wang J, Lou P, Lesniewski R, Henkin J. (2003). Paclitaxel at ultra low concentrations inhibits angiogenesis without afecting cellular microtubule assembly. Anticancer Drugs, 14, 13-19.
208. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. (2010). Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 468, 829-833.
209. Wang Y, Oliver G. (2010). Current views on the function of the lymphatic vasculature in health and disease. Genes Dev, 24, 2115-2126.
210. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res, 69, 2400-2407.
211. Wang ZA, Shen MM. (2011). Revisiting the concept of cancer stem cells in prostate cancer. Oncogene, 30, 1261-1271.
212. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-López AJ. (1999). Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res, 5, 3281s-3286s.
213. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. (2003). Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol, 160, 267-277.
214. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol, 9, 893-904.
215. Wu J, Akaike T, Maeda H. (1998). Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res, 58, 159-165.
216. Wu K, Liu J, Johnson RN, Yang J, Kopecek J. (2010). Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl, 49, 1451-1455.
217. Wu K, Yang J, Liu J, Kopecek J. (2012). Coiled-coil based drug-free macromolecular therapeutics: In vivo efcacy. J Control Release, 157, 126-131.
218. Yan Z, Wang F, Wen Z, Zhan C, Feng L, Liu Y, Wei X, Xie C, Lu W. (2012). LyP-1-conjugated PEGylated liposomes: A carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release, 157, 118-125.
219. Yan Z, Zhan C, Wen Z, Feng L, Wang F, Liu Y, Yang X, Dong Q, Liu M, Lu W. (2011). LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics. Nanotechnology, 22, 415103.
220. Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell, 14, 818-829.
221. Yang J, Luo K, Pan H, Kopecková P, Kopecek J. (2011). Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates. React Funct Polym, 71, 294-302.
222. Yilmaz OH, Valdez R, Teisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 441, 475-482.
223. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutof size. Cancer Res, 55, 3752-3756.
224. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res, 54, 4564-4568.
225. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-1123.
226. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, Wu H, Li L. (2006). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature, 441, 518-522.
227. Zhou Y, Yang J, Kopecek J. (2012). Selective inhibitory efect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials, 33, 1863-1872.